Clinical trials
Prostatic Cancer clinical trials
Below are recruiting prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,215 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03620786Recruiting
HIFU experience study for treating parts of the prostate
This observational study looks at outcomes after people choose HIFU (high-intensity focused ultrasound) to treat only a targeted area of the prostate. It may help doctors better understand how well HIFU works and what follow-up imaging or testing shows over time.
Los Angeles, CaliforniaAges 40–85 - NCT04104607RecruitingPhase 1
Testing a PSMA-targeted immune drug for advanced prostate cancer
This Phase 1 study tests a new drug that aims to attach to PSMA on prostate cancer cells and activate T-cells (an immune cell type) to attack the cancer. It is for men with advanced prostate cancer that no longer responds to hormone therapy, especially after several prior treatments.
Tübingen, Baden-WurttembergAges 18 years+ - NCT05715502Recruiting
Targeted radiation for prostate cancer that came back
This study tests a focused (“salvage”) brachytherapy—radiation placed directly near the prostate—to treat prostate cancer that has returned after earlier radiation. It may help control the tumor while limiting radiation exposure to surrounding tissues, based on how well people fit the study’s safety and cancer details.
Poznan, Greater Poland VoivodeshipAges 18 years+ - NCT05810467Recruiting
Active surveillance study for men at higher risk prostate cancer
This trial studies how well “active surveillance” works for men with prostate cancer who are considered higher risk because of family history or genetics. It aims to safely monitor the cancer and decide the best timing for treatment if needed, while tracking side effects and follow-up success.
Sutton, SurreyAges 18 years+ - NCT05864196RecruitingPhase 1
Testing two-shot prostate radiation with MRI-guided planning
This early-phase study tests a prostate radiation approach given in two treatments, planned using MRI. It’s designed for men with lower-to-intermediate risk prostate cancer and aims to see if this method is safe and works well.
Mineola, New YorkAges 18 years+ - NCT06334809Recruiting
Genetic test for men with prostate cancer and DNA repair changes
This trial looks for specific DNA repair changes in men with prostate cancer. It tests if these genetic features can help guide treatment decisions. You may join if you have high-risk localized, newly metastatic, or advanced prostate cancer and have tissue available for testing.
Candiolo, TurinAges 18 years+ - NCT06423976Recruiting
Studying microbes in prostate cancer tumors
This trial collects tumor samples from men with prostate cancer to study the bacteria and other microbes inside the tumor. It aims to learn how these microbes might affect the cancer and treatment.
Sutton, SurreyAges 18 years+ - NCT06600698RecruitingPhase 1/Phase 2
Herbal supplement for rising PSA in prostate cancer
This study tests an herbal supplement called AGN-INM176 in men with prostate cancer whose PSA is rising but whose cancer has not spread. It aims to see if the supplement can safely slow PSA rise without the need for hormone therapy or other treatments.
Hershey, PennsylvaniaAges 40 years+ - NCT06612034Recruiting
Prostate cancer provider survey on care gaps
This study surveys doctors who treat prostate cancer to understand differences in care. It aims to find ways to make care more equal for all patients.
Ankara, AnkaraAges Any age - NCT06774781Recruiting
Using MRI to find prostate tumors
This study uses advanced MRI scans to better identify prostate cancer lesions before biopsy or surgery. It may help men who already have suspicious MRI findings and are scheduled for a prostate biopsy or removal.
BolognaAges 18 years+ - NCT06826768RecruitingPhase 1
Study of REGN5678 plus cemiplimab for advanced prostate cancer
This trial tests a combination of two drugs (REGN5678 and cemiplimab) for men with metastatic castration-resistant prostate cancer that has progressed after at least two prior treatments. The goal is to see if this new combination can help shrink the cancer or slow its growth.
Houston, TexasAges 18 years+ - NCT06985238Recruiting
Study of MRI for prostate cancer screening
This study tests a new MRI platform to better identify prostate issues before a biopsy. It is for people with elevated PSA whose doctor is considering a biopsy.
Rochester, New YorkAges 40–90 - NCT05043012Recruiting
Testing a special MRI scan for prostate cancer diagnosis
This study checks how well a new prostate MRI scan (using a flexible coil and multiple MRI types) can correctly identify prostate cancer and help with treatment planning. You may be able to help doctors improve prostate imaging before you have surgery.
Houston, TexasAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT07755592Recruiting
Using a blood test to find prostate cancer early
This study uses a simple blood test to look for microRNA patterns that may help spot prostate cancer earlier and avoid unnecessary biopsies. If you have elevated PSA or suspicious findings, this test might give more information about your risk.
ShanghaiAges 18 years+ - NCT06276465RecruitingPhase 3
Darolutamide with or without radiation for advanced prostate cancer
This trial tests whether adding radiation therapy to the drug darolutamide helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and has spread to a few spots seen on special scans. The study aims to find the best way to control the cancer while keeping side effects manageable.
LorientAges 18 years+ - NCT06637267Recruiting
Testing a new blood test to improve prostate cancer risk assessment
This trial is testing a new blood test (Proclarix) to see if it can better predict prostate cancer risk in men who are already scheduled for an MRI and prostate biopsy. The goal is to improve how doctors decide who needs a biopsy.
Aarau, Canton of AargauAges 45–80 - NCT06672926Recruiting
New Prostate MRI Pathway for Radiographers
This trial tests a new way for experienced MRI radiographers to review prostate MRI scans, aiming to improve the diagnostic pathway for prostate cancer. It may help patients by leading to faster and more accurate results.
Stoke-on-Trent, StaffordshireAges Any age - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT06022822RecruitingPhase 2
Urolithin A supplement before prostate cancer surgery
This trial tests whether taking a supplement called urolithin A for a few weeks before prostate removal surgery can help. The supplement comes from pomegranates and may slow cancer growth. You may qualify if you have prostate cancer, are planning surgery within 3-6 weeks, and have not had prior treatment like hormone therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT06923657Recruiting
PSMA PET/MRI for guiding biopsy after negative MRI
This study tests whether a special type of PET/MRI scan (PSMA PET/MRI) can help doctors find hidden prostate cancer in men who have a rising PSA but previous negative biopsies and a non-suspicious MRI. It aims to improve detection without skipping needed treatment.
Fuzhou, FujianAges 30–85 - NCT04896801Recruiting
MRI-guided radiation for certain prostate cancer risks
This trial tests a precise, MRI-guided radiation treatment given over 7 days for people with prostate cancer in specific risk categories. It may help shrink or control the cancer while carefully targeting the tumor.
BrusselsAges 18 years+ - NCT05786742Recruiting
Radiation plan test for early prostate cancer with a boost
This trial tests a more concentrated radiation schedule for early-stage prostate cancer, using an extra high-dose “boost” delivered from inside the body. It may help by treating the prostate more precisely while aiming to keep side effects manageable.
QuébecAges 18–95
Hear when a new Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatic cancer?
- Yes. Clin2 currently lists 1,215 recruiting prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.